Description: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and the NDA for SequestOxâ¢, for which it received the CRL from the FDA. EliteâÂÂs lead pipeline products include abuse-deterrent opioids which utilize the CompanyâÂÂs patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.
Home Page: www.elitepharma.com
165 Ludlow Avenue
Northvale,
NJ
07647
United States
Phone:
201 750 2646
Officers
Name | Title |
---|---|
Mr. Nasrat Hakim | Chairman, CEO & Pres |
Mr. Douglas Plassche | Exec. VP of Operations |
Mr. Robert Chen | CFO, Sec. & Treasurer |
Ms. Dianne Will | VP of Investor Relations & Corp. Affairs |
Dr. George Kenneth Smith J.D., M.B.A., Ph.D. | VP of Legal |
Dr. Sophy Abraham | Head of Regulatory Affairs |
Mr. Kirko Kirkov | Chief Commercial Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 3 |
Price-to-Book MRQ: | 1.1186 |
Price-to-Sales TTM: | 0.9244 |
IPO Date: | 1998-07-23 |
Fiscal Year End: | March |
Full Time Employees: | 43 |